检索结果-南通市图书馆

Emerging therapeutic options for the management of hepatitis C infection

World Journal of Gastroenterology 2014年第23期20卷 7079-7088页

作者： J Richard Thompson Department of Pharmacy Practice One University Park DriveLipscomb University College of PharmacyNashvilleTN 37204United States

Until recently the traditional treatment for hepatitis C infection included pegylated interferon and ribavirin combination *** sustained virological response(SVR)seen with this combination is poor and requires lengthy treatment to ***,significant side effects and numerous contraindications prevented many patients from being successfully treated with this *** 2011,two new protease inhibitors,telaprevir and boceprevir,were approved for use with pegylated interferon and ribavirin in the United States by the United States Food and Drug *** agents have significantly improved SVR rates;however significant problems with toxicity remain including severe skin rash and *** are a wide range of compounds in late stage development for the future treatment of hepatitis C that exploit many different mechanisms of viral *** of these compounds include additional protease inhibitors,like telaprevir and boceprevir,as well as inhibitors of other nonstructural proteins in the viral genome such as NS5A and NS5B,and compounds that target host proteins within the *** of these agents are being developed for oral administration once daily and various combinations are being assessed for use without the need for pegylated interferon and *** paper reviews agents in late phase development that may be commercially available within 1-2 years.

关键词： Hepatitis C Pharmacotherapy Interferon Ribavirin Protease inhibitors Polymerase inhibitors cyclophilin inhibitors

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Emerging therapeutic options for non-alcoholic fatty liver disease:A systematic review

引用

世界肝病学杂志:英文版(电子版) 2023年第8期15卷 1001-1012页

作者： Jasmine Tidwell Natalie Balassiano Anjiya Shaikh Mahmoud Nassar Department of Internal Medicine University of ConnecticutFarmingtonCT 06032United States Department of Internal Medicine Icahn School of Medicine at Mount Sinai/NYC Health+Hospitals/QueensNew YorkNY 11432United States Department of Internal Medicine Division of EndocrinologyDiabetes and MetabolismJacobs School of Medicine and Biomedical SciencesUniversity of BuffaloBuffaloNY 14221United States

BACKGROUND Non-alcoholic fatty liver disease(NAFLD)has become a prevalent cause of chronic liver disease and ranks third among the causes of *** the United States alone,annual medical costs are approximately 100 billion ***,there is no Federal Drug Administration(FDA)-approved medication for its ***,various clinical trials are investigating several therapeutic classes that could potentially treat *** is valuable to have a compilation of the data available on their *** To assess the efficacy of cyclophilin inhibitors,fibroblast growth factor 21 analogs(FGF21),and dual and pan peroxisome proliferator-activated receptor(PPAR)agonists for treating *** A comprehensive literature search using keywords including cyclophilin inhibitor,FGF agonist,pan-PPAR agonists,dual-PPAR agonist,NAFLD,nonalcoholic steatohepatitis,and fatty liver was conducted on October 29,2022,in PubMed,EMBASE,Cochrane Library,Scopus and Web of *** and human research,case reports,and published articles in English from all countries with patients aged 18 and above were *** articles with a National Institutes of Health(NIH)Quality Assessment score of five or higher out of eight points were *** that were narrative or systematic reviews,abstracts,not in English,focused on patients under 18 years old,did not measure outcomes of interest,were inaccessible,or had a low NIH Quality Assessment score were *** article was screened by two independent researchers evaluating relevance and *** were scored based on the NIH Quality Assessment Score;then,pertinent data was extracted in a spreadsheet and descriptively *** Of the 681 records screened,29 met the necessary criteria and were included in this *** records included 12 human studies and 17 animal ***,there were four studies on cyclophilin inhibitors,four on FGF agonists/analogs,eleven on pan-PPAR

关键词： Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis cyclophilin inhibitors Fibroblast growth factor 21 analogs Dual peroxisome proliferator-activated receptor agonists Pan peroxisome proliferator-activated receptor agonists

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：